Alzamend Neuro, Inc. ALZN

Overview

Alzamend Neuro, Inc., established in 2016 and based in Atlanta, Georgia, operates as a clinical-stage biopharmaceutical enterprise dedicated to confronting neurodegenerative and psychiatric conditions through innovative therapeutic solutions. Its commitment spans the rigorous development of novel products aiming to address a variety of mentally debilitating conditions. Through strategic partnerships, including a notable agreement with Massachusetts General Hospital for the Phase II clinical trial of one of its key products, Alzamend Neuro, Inc. seeks to forge ahead in the biotechnology sphere, positioning itself as a beacon of hope for patients suffering from these challenging diseases.

Products and Services

• AL001:

This product signifies a therapeutic composite combining lithium, proline, and salicylate, designed to treat a range of disorders including Alzheimer's, bi-polar disorder, major depressive disorder, post-traumatic stress disorder, other neurodegenerative diseases, and various psychiatric conditions. By integrating these components, AL001 aims to offer a multifaceted approach to managing symptoms and improving the quality of life for those affected by these serious conditions.

• ALZN002:

The innovative approach of ALZN002 lies in its use of a method that employs a mutant-peptide sensitized cell as a cell-based therapeutic vaccine. This advance seeks to rejuvenate a patient’s immune system, empowering it to combat Alzheimer's disease more effectively. This cell-based therapeutic vaccine represents a revolutionary step in the treatment of Alzheimer's by potentially halting or reversing the progress of the disease through immunological intervention.